Abstract
1.0 % Mol of K3PO4·3H2O was found to catalyze aminohalogenation reaction of nitrostyrenes with N,N-dibromo-tert-butylcarbamate (t-Boc-NBr2) in dichloroethane system. Good to excellent yields and complete regioselectivity have been achieved by taking advantage of the GAP work-up without using traditional purification techniques such as column chromatography and recrystallization. New mechanism was proposed involving radical and ionic catalytic cycles and an intramolecular migration.
Keywords: Aminohalogenation; bromoamine; Group-Assistant-Purification (GAP) chemistry; N,N-dibromo-tert-butylcarbamate; nitrostyrenes
Introduction
Aminohalogenation reaction has become an important tool for the synthesis of vicinal haloamine compounds that are versatile building blocks in organic and medicinal chemistry.1-6 For example, they can be readily converted into many other synthetic precursors, such as aziridines and enamines. In the past one decade, many efforts have been devoted to this reaction under a series of metal-catalyzed and organocatalytic conditions. Functionalized substrates, such as α,β-unsaturated carboxylic esters,4,5 α,β-unsaturated nitriles,7 α,β-unsaturated ketones,8 β-nitrostyrenes9 and other substrates5,10, have been proven to be suitable for aminohalogenation reaction. In the meanwhile, several nitrogen/halogen sources including N,N-dichlorotoluenesulfonamide (TsNCl2),4,5 NsNCl2/NsNHNa,4 N-bromoacetamide,11 Chloramine-T,11 pTsNH2/NBS,12 NsNCl2/NsNH2,13 tert-butyl-N,N-dibromo- and dichlorocarbamates14 have been found to be efficient for aminohalogenation reaction with very well controlled regio and stereoselectivity. The reaction is believed to go through the formation of aziridinium intermediates, halonium (bromonium or chloronium) intermediates or radicals. Aziridinium intermediate-based mechanism has been confirmed by the direct formation of imidazoline products that serve as a new protocol for the synthesis of diamino compounds.1b, 14
Very recently, we established a new concept called the GAP chemistry (Group-Assistant-Purification chemistry). This chemistry can avoid the use of traditional purification method such as chromatography or recrystallization and the pure products can be obtained simply by washing the solid crude products with organic solvents.15-17 This new concept is attributed to the discovery of achiral/chiral N-phosphonyl and chiral N-phosphinyl imine reagents and their reactions. The characteristics of GAP chemistry requires the functional groups of starting materials should enable the resulting products to have adequate solubility, i.e., the products must be dissolved some solvents (e.g., THF, DCM, etc.) for further transformations, but should not be readily dissolved in others (e.g., hexane, petroleum ether, their mixtures with EtOAc, etc.); the functional groups should enable their attached substrates to have efficient chemical reactivity toward various species; For asymmetric reactions, the functional groups should be able to show efficient asymmetric induction and control; the functional groups should have great flexibility for structural modifications so that both physical (e.g., solubility) and chemical properties (tolerable to further transformations) of resulting products can be readily adjusted; the functional group-attached auxiliaries can be cleavable under various conditions and recycled for re-use. So far, controlling solubility of organic products via designing auxiliaries has been very challenging in chemical synthesis. The N-phosphonyl and N-phosphinyl functional group-based GAP chemistry has been proven to meet this purpose due to the special polarity of P=O bonds in which adequate amount of negative charge and positive charge localized on oxygen and phosphorous, respectively. We are pleased to find that this concept can be extended to other reactions such as aminohalognation of olefins as shown in this article.
Results and Discussion
The present aminobromination reaction is based on the use of β-nitrostyrenes as the substrates due to their high flexibility for further transformations. The reaction was performed in 1,2-dichloroethane at room temperature without using inert gas protection (Scheme 1). The loading of 1.0 mol % K3PO4·3H2O was able to efficiently catalyze the reaction to completion within one hour affording vicinal bromoamine products in good to excellent yields (up to 99 %). Since several polar functional groups, nitro, t-Boc and two bromo moieties, exist in the structures of resulting products, they can lower the solubility of product in organic solvents and enable GAP purification to be performed. Small amounts of impurities are either dissolved in liqueur or washed away simply by washing with some organic solvents.
Scheme 1.

At the beginning, we did the reaction according to the literature procedure.13 As anticipated that nitrostyrene as a difficult for aminobromination substrate did not result in any products when it was subjected to the reaction with tert-butyl-N,N-dibromocarbamate for up to 16 hours in dichloromethane at room temperature. Screening of a series of organic bases, inorganic bases and salts was carried out. Several organic bases include DMAP, DIPEA, triethylamine, triphenylphosphine. We found these common organic bases afforded no or trace amounts of products as monitored by TLC. Inorganic salts such as sodium fluoride, NaOAc, KHCO3, NaHCO3, K2HPO4 were also proven to be ineffective giving no product either. 10 mol% of Na2CO3, K2CO3, anhydrous Na3PO413 and Ca(OH)2 resulted in less than 49% of vicinal aminobromides within 1 hour as monitored by TLC determination. Two stronger based, sodium and potassium hydroxide give good yields of 86% and 81%, respectively. Pleasantly, when anhydrous K3PO418 and K3PO4·3H2O were employed as the catalyst, more than 90% chemical yield was achieved under the same condition; similar results were obtained by decreasing the catalyst loading to 5.0 mol % and 2.5 mol%, respectively. The above reaction was performed by reacting 1.0 mmol of nitrostyrene with 1.2 mmol of tert-butyl-N,N-dibromocarbamate in 2.5 mL of dichloromethane at room temperature. However, when the catalyst loading was decreased to 1.0 mol%, no product was observed. However, then the volume of solvent was changed from 2.5 to 1.0 mL, > 90% of chemical yield was obtained.
To explore further improvements, we next examined a series of solvents. Three solvents, ethyl acetate, acetonitrile and acetone gave very poor yields (5-37%); three other solvents, THF, DMF and ethanol did not show any products. However, 1,2-dichloroethane was found to be even more effective and resulted in a almost quantitative yield when the reaction was performed by using 1.2 equiv of tert-butyl-N,N-dibromocarbamate in the presence 1.0 mol% of K3PO4·3H2O in 1.0 mL of solvent within one hour. The actual loading of K3PO4 is lower than 1.0 mol% if water is excluded from the above stoichiometric calculation.
Since K3PO4·3H2O was used in a tiny amount (1.0 mol%), after it was added into reaction mixture containing tert-butyl-N,N-dibromocarbamate and nitrostyrene in 1,2-dichloroethane, it can be dissolved well. At the beginning, the color of reaction mixture was yellow; it gradually became light greenish as the reaction proceeds for 20-30 min.
The preparation of tert-butyl-N,N-dibromocarbamate was performed by following the literature procedure.13 In its synthesis, a modification was made by replacing potassium carbonate with KOH to give a quantitative yield. Essentially, there is no need for further purification of the crude tert-butyl-N,N-dibromocarbamate after work-up was performed; it was directly subjected to the aminobromination reaction with nitrostyrene. It should be pointed out that as compared with the known procedure by Zwierzak and coworkers in which crude product was contaminated with about 9% of tert-butyl N bromocarbamate, the present modification would provide an alternative and more efficient approach to tert-butyl-N,N-dibromocarbamate on large scale. In addition, this synthesis belongs to our GAP chemistry in which the products were purified without using chromatography and recrystallization.
After the catalytic system was established, we investigated the substrate scope of this aminobromination reaction by using a variety of nitrostyrene derivatives with substituents on their aromatic rings. As shown in Table 1, this reaction showed a great substrate scope in which twenty substrates were proven to be suitable for this system. There is no particular trend for these substrates. Most electron-withdrawing group (EWG)-attached substrates gave nearly quantitatively chemical yields (entries 2,4,7,13 & 15, Table 1); only 4-CF3 and two dichloro substituted ones (entries 6, 11 & 12, Table 1) gave slightly lower yields of 91%, 92% and 88%, respectively. Interestingly, strong-electron-donating group (EDG)-attached substrates usually give lower chemical yields as compared with those with neutral and EWG-attached ones, but in this catalytic system, 2-MeO-Ph and 3,4-(MeO)2-Ph cases also afforded the vicinal aminobromide products in quantitatively yields (entries 18 & 19, Table 1). Two other EDG cases, 4-MeO-Ph and 2-BnO-Ph, also showed excellent yields of 94% and 95%, respectively (entries 3 and10, Table 1). There are no side-products generated from bromination on phenyl rings observed as at all. It is not clear why two neutral cases, 1-naphthyl and 4-butyl-Ph (entries 9 and 20, Table 1), resulted in lowest chemical yields of 82% and 83%, respectively. As mentioned that this reaction resulted in vicinal aminobromide products which can be purified via GAP process without the use of traditional column chromatography and recrystallization, i.e., after work-up is done, the pure product can be readily obtained simply by washing the crude product with organic solvents (in this case, hexane). We also conducted the reaction of nitrostyrene on a scale of 3.0 g (20 mmol) and obtained product 1b in almost quantitative yield (Scheme 2), which indicates that the present reaction is promising for large scale production. The vicinal aminobromide products have been fully determined by NMR spectroscopic, HR-MS analysis, etc.; and the product of 3a has been unambiguously analyzed by X-ray diffractional analysis with the ORTEP diagram presented in Figure 1 (see SI).
Table 1.
K3PO4·3H2O-catalyzed aminobromination of nitrostyrenes[a]

| Entry | Ar | Product | Yield (%)[b] |
|---|---|---|---|
| 1 | Ph | 3a | 98 |
| 2 | 4-Cl-C6H4 | 3b | 98 |
| 3 | 4-MeO-C6H4 | 3c | 94 |
| 4 | 2-Cl-C6H4 | 3d | 99 |
| 5 | 4-Me-C6H4 | 3e | 95 |
| 6 | 4-CF3-C6H4 | 3f | 91 |
| 7 | 4-CN-C6H4 | 3g | 97 |
| 8 | 2-naphthyl | 3h | 91 |
| 9 | 1-naphthyl | 3i | 82 |
| 10 | 2-BnO-C6H4 | 3j | 95 |
| 11 | 2, 6-Cl2-C6H3 | 3k | 92 |
| 12 | 3, 4-Cl2-C6H3 | 3l | 88 |
| 13 | 4-F-C6H4 | 3m | 99 |
| 14 | 4-Br-C6H4 | 3n | 96 |
| 15 | 3-F-C6H4 | 3o | 98 |
| 16 | 3-Br-C6H4 | 3p | 86 |
| 17 | 3-Br-4-MeO-C6H3 | 3q | 88 |
| 18 | 2-MeO-C6H4 | 3r | 98 |
| 19 | 3, 4-(CH3O)2-C6H3 | 3s | 98 |
| 20 | 4-Butyl-C6H4 | 3t | 83 |
Conditions: 1a (1.0 mmol), BocNBr2 (1.2 mmol), with K3PO4·3H2O (0.01 mmol) in (CH2Cl)2 (1 ml) at room temperature for 60 min.
Isolated yields.
Scheme 2.

This reaction is suggested to proceed through free-radical chain stage and ionic catalytic cycle (Scheme 3). The first stage of radical mechanism has been proposed for the reaction of t-Boc-NBr2 with styrene in literature.13 This catalytic cycle involves the common spontaneous initiation, propagation and radical termination to generate the monobromide intermediate (A). The deprotonation of A by PO43− leads to the formation of intermediate B and P(OH)O32−. The intramolecular migration of bromine from amide nitrogen onto carboanion to give intermediate C in which the negative charge can be shifted onto oxygen of t-Boc group. Two contributing structures exist for this negative charge shifting. The protonation of C by P(OH)O3− affords the final product 3a, and concurrently gives the catalytic species, PO43−, back for continuing cycles of stage 2. This mechanistic hypothesis can account for the following observations: (1) several common bases, such as KOH, NaOH, Ca(OH)2, K2CO3, etc, can also serve as the catalysts for this reaction, albeit they are not as efficient as K3PO4; (2) Only 1.2 equv. of t-Boc-NBr2 (no need for 2.0 equiv) is needed for the complete consumption of the starting material of nitrostyrene.
Scheme 3.

It should be noted that the present work represents the first GAP chemistry example of non-imine-based reactions in our labs. It can encourage synthetic chemists to find more GAP preparations so as to reduce the consumption of organic solvents and silica gels for column chromatography. Therefore, the use of nature’s energy resources and manpower can be minimized due to the fast synthesis GAP chemistry. If GAP is employed for pharmaceutical and industrial productions on large scales, the environmentally contaminations can also be reduced substantially.
In conclusion, we have demonstrated a concise and efficient aminobromination of β-nitrostyrene derivatives with N,N-dibromocarbamate as nitrogen/bromine sources in the presence of 1.0 mol% of K3PO4·3H2O as catalyst. This reaction proceeded smoothly and environmentally friendly to give the β,β-dibromo Boc-protected amines in complete regioselectivity and good to excellent yields (82 ~ 99%). By using 1.2 equiv of nitrogen/bromine sources, the reaction can occur to completion within one hour at room temperature without using protection of inert gases. The GAP chemistry was found to be suitable for simple purifying the products without using traditional purification techniques of column chromatography and recrystallization. A mechanism involving spontaneously initiated free-radical chain and ionic catalytic cycles was proposed to account for experimental observations. Finally, this reaction showed promising result for practical scale up synthesis.
Experimental Section
General
Commercial chemicals and solvents were used without any further purification. Melting points were uncorrected. IR spectra were collected in KBr pellets. 1H-NMR, 13C-NMR (TMS used as internal standard) spectra were collected in CDCl3. High-resolution mass spectra for all the new compounds were collected on Q-TOF instrument (ESI).
Procedure for preparing BocNBr2
To a stirred solution of BocNH2 (5.86 g, 50 mmol) and NaOH (4.0 g, 0.1 mol) in water (50 mL) was added bromine Br2 (19 g, 0.12 mol) dropwise at room temperature and stirred another 2 h. When the reaction completed, lot of orange solid was formed, which was filtered to get the crude product. The residue was dissolved in CH2Cl2, washed with brine, dried with anhydrous Na2SO4, and concentrated to get the pure product(13.7g, quant). Mp = 93–94 °C (lit13a 93-95 °C). 1H-NMR (300 MHz, CDCl3) δ 1.49 (s, 9H).
Typical procedure for the aminobromination reaction
Into a vial was added 1a (149 mg, 1 mmol), BocNBr2 (330 mg, 1.2 mol), K3PO4·3H2O (2.7 mg, 1 mol %), (CH2Cl)2 (1.0 mL) and stirred 60 min at room temperature. The reaction completion was indicated by TLC and the color change which turned from yellow to light green. The reaction mixture was washed with brine, and the aqueous phase extracted with DCM. The organic layer was dried with anhydrous Na2SO4, concentrated to nearly dryness to give a solid/oil mixture. A tiny amount of oil was washed away by hexane; if more oil stuck on solid product appeared, 10 mL of hexane was added into the above mixture which was heated to give a solution mixture containing white solids. After cooling to room temperature, solution was filtrated off to afford pure product 3a.
1-tert-Butoxyl-formamido-2,2-dibromo-1-phenyl-2-nitroethane (3a)
White solids (415 mg, 98 %). Mp = 122–124 °C. 1H NMR (300 MHz, CDCl3) δ 7.45–7.35 (m, 5H), 5.97 (d, J = 10.20 Hz, 1H), 5.60 (d, J = 9.60 Hz, 1H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.8, 133.5, 129.4, 129.0 (2), 128.4 (2), 94.5, 81.1, 64.4, 28.0 (3) ppm. IR (KBr): ν = 3313, 2976, 1693, 1572, 1520, 1456, 1367, 1319, 1248, 1167, 837, 700 cm−1. MS (ESMS/[M+Na]+): calcd for C13H16Br2N2O4Na: 446.9349; found 446.9331.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(4-chlorophenyl)-2-nitroethane (3b)
White solids (449 mg, 98 %). Mp = 121–123 °C. 1H NMR (300 MHz, CDCl3) δ 7.39 (d, J = 9.00 Hz, 2H), 7.35 (d, J = 8.70 Hz, 2H), 5.95 (d, J = 9.30 Hz, 1H), 5.55 (d, J = 9.90 Hz, 1H), 1.43 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.7, 135.6, 132.1, 130.4 (2), 128.6 (2), 93.8, 81.3, 63.9, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C13H15Br2ClN2O4Na: 480.8958; found 480.8944. IR (KBr): ν = 3278, 2978, 1687, 1577, 1514, 1369, 1323, 1250, 1163, 831 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(4-methoxyphenyl)-2-nitroethane (3c)
White solids (427 mg, 94 %). Mp = 129–131 °C. 1H NMR (300 MHz, CDCl3) δ 7.34 (d, J = 9.00 Hz, 2H), 6.89 (d, J = 9.00 Hz, 2H), 5.91 (d, J = 10.20 Hz, 1H), 5.54 (d, J = 9.60 Hz, 1H), 3.81 (s, 3H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 160.2, 153.9, 130.2 (2), 125.4, 113.7 (2), 95.0, 81.0, 64.0, 55.1, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C14H18Br2N2O5Na: 476.9455; found 476.9453. IR (KBr): ν = 3313, 2976, 1689, 1576, 1508, 1302, 1244, 1169, 1034, 837 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(2-chlorophenyl)-2-nitroethane (3d)
White solids (454 mg, 99 %). Mp = 164–166 °C. 1H NMR (300 MHz, CDCl3) δ 7.60 (br, 1H), 7.49–7.45 (m, 1H), 7.38–7.34 (m, 2H), 6.70 (d, J = 10.20 Hz, 1H), 5.56 (br, 1H), 1.42 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.4, 135.6, 133.1, 130.6, 130.1, 128.4, 127.1, 93.1, 81.6, 59.8, 28.1 (3) ppm. MS (ESMS/[M+Na]+): calcd for C13H15Br2ClN2O4Na: 480.8958; found 480.8941. IR (KBr): ν = 3357, 2987, 1709, 1577, 1473, 1365, 1155, 1045, 843cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(p-tolyl)-2-nitroethane (3e)
White solids (416 mg, 95 %). Mp = 108–110 °C. 1H NMR (300 MHz, CDCl3) δ 7.31 (d, J = 8.10 Hz, 2H), 7.18 (d, J = 8.10 Hz, 2H), 5.93 (d, J = 9.30 Hz, 1H), 5.56 (d, J = 9.00 Hz, 1H), 2.35 (s, 3H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.8, 139.4, 130.5, 129.0 (2), 128.8 (2), 94.8, 81.0, 64.3, 28.0, 21.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C14H18Br2N2O4Na: 460.9506; found 460.9479. IR (KBr): ν = 3292, 2978, 1687, 1577, 1509, 1323, 1250, 1161, 1022, 845cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(4-(trifluoromethyl)phenyl)-2-nitroetha ne (3f)
White solids (448 mg, 91 %). Mp = 113–115 °C. 1H NMR (300 MHz, CDCl3) δ 7.65 (d, J = 8.70 Hz, 2H), 7.59 (d, J = 8.10 Hz, 2H), 6.04 (d, J = 10.20 Hz, 1H), 5.60 (d, J = 10.50 Hz, 1H), 1.43 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.8, 137.7, 131.6 (q, J = 32.82 Hz), 129.6 (2), 125.4, 125.3, 121.8, 93.2, 81.6, 64.1, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C14H15Br2F3N2O4Na: 514.9223; found 514.9231. IR (KBr): ν = 3319, 2981, 1687, 1579, 1510, 1327, 1250, 1132, 1070, 839cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(4-cyanophenyl)-2-nitroethane (3g)
White solids (435 mg, 97 %). Mp = 146–148 °C. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J = 8.40 Hz, 2H), 7.59 (d, J = 8.40 Hz, 2H), 6.03 (d, J = 10.20 Hz, 1H), 5.58 (d, J = 9.60 Hz, 1H), 1.43 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.6, 138.7, 131.9 (2), 129.9 (2), 117.8, 113.2, 92.6, 81.4, 63.9, 27.8 (3) ppm. MS (ESMS/[M+Na]+): calcd for C14H15Br2N3O4Na: 471.9302; found 471.9315. IR (KBr): ν = 3315, 2979, 2239, 1730, 1576, 1502, 1327, 1244, 1159, 833cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(naphthalen-2-yl)-2-nitroethane (3h)
White solids (431 mg, 91 %). Mp = 139–141 °C. 1H NMR (300 MHz, CDCl3) δ 7.91–7.84 (m, 4H), 7.55-7.52 (m, 3H), 6.16 (d, J = 9.60 Hz, 1H), 5.72 (d, J = 10.20 Hz, 1H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.9, 133.3, 132.5, 130.8, 129.3, 128.2, 128.1, 127.5, 127.0, 126.6, 125.5, 94.4, 81.2, 64.6, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C17H18Br2N2O4Na: 496.9506; found 496.9549. IR (KBr): ν = 3261, 3149, 2983, 1709, 1574, 1506, 1363, 1254, 1159, 1018cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(naphthalen-1-yl)-2-nitroethane (3i)
White solids (389 mg, 82 %). Mp = 201–203 °C. 1H NMR (300 MHz, CDCl3) δ 8.42 (d, J = 7.50 Hz, 1H), 7.91 (t, J = 8.40 Hz, 2H), 7.78 (d, J = 6.60 Hz, 1H), 7.65 (t, J = 7.20 Hz, 1H), 7.56 (d, J = 8.10 Hz, 1H), 7.51 (d, J = 8.10 Hz, 1H), 7.00 (d, J = 9.00 Hz, 1H), 5.71 (d, J = 8.40 Hz, 1H), 1.40 (s, 9H) ppm. 13C NMR (75.45 MHz, DMSO-d6) δ 154.8, 133.1, 131.5, 131.4, 129.8, 128.9, 127.3, 126.9, 125.9, 125.0, 123.0, 94.4, 79.7, 57.8, 27.9 (3) ppm. MS (ESMS/[M+Na]+): calcd for C17H18Br2N2O4Na: 496.9506; found 496.9505. IR (KBr): ν = 3240, 3134, 2977, 1693, 1577, 1361, 1257, 1159, 1049, 775 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(2-(benzyloxy)phenyl)-2-nitroethane (13j)
White solids (504 mg, 95 %). Mp = 120–122 °C. 1H NMR (300 MHz, CDCl3) δ 7.50–7.32(m, 7H), 6.99 (d, J = 8.10 Hz, 2H), 6.39 (d, J = 9.60 Hz, 1H), 6.15 (d, J = 7.20 Hz, 1H), 5.15(s, 2H) 1.43 (s, 9H) ppm. 13C NMR (75.45 MHz, DMSO-d6) δ 155.6, 154.4, 136.8, 130.4, 129.8, 128.3 (2), 127.7 (2), 127.2, 123.8, 120.4, 112.4, 95.0, 79.4, 69.6, 56.7, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C20H22Br2N2O5Na: 552.9769; found 552.9737. IR (KBr): ν = 3246, 3141, 2978, 1699, 1574, 1493, 1367, 1252, 1161, 1020, 748 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(2,6-dichlorophenyl)-2-nitroethane(3k)
White solids (454 mg, 92 %). Mp = 104–106 °C. 1H NMR (300 MHz, CDCl3) δ 7.45(d, J = 7.80 Hz, 1H), 7.35–7.24 (m, 2H), 7.12 (d, J = 10.50 Hz, 1H), 6.43 (d, J = 9.30 Hz, 1H), 1.45 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.8, 138.6, 134.4, 130.7, 130.6, 130.0, 129.1, 91.6, 81.4, 62.3, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C13H14Br2Cl2N2O4Na: 514.8567; found 514.8554. IR (KBr): ν = 3323, 2976, 1703, 1577, 1439, 1348, 1254, 1155, 1014, 769 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(3,4-dichlorophenyl)-2-nitroethane (3l)
White solids (434 mg, 88 %). Mp = 156–158 °C. 1H NMR (300 MHz, CDCl3) δ 7.57 (s, 1H), 7.46 (d, J = 8.40 Hz, 1H), 7.29 (d, J = 8.40 Hz, 1H), 5.94 (d, J = 9.60 Hz, 1H), 5.55 (br, 1H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.7, 134.0, 133.9, 132.7, 131.0, 130.4, 128.5, 93.0, 81.7, 63.5, 28.1 (3) ppm. MS (ESMS/[M+Na]+): calcd for C13H14Br2Cl2N2O4Na: 514.8567; found 514.8557. IR (KBr): ν = 3353, 3151, 2976, 1705, 1572, 1473, 1369, 1254, 1159, 1022, 777 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(4-fluorophenyl)-2-nitroethane (3m)
White solids (438 mg, 99 %). Mp = 118–120 °C. 1H NMR (300 MHz, CDCl3) δ 7.42 (dd, J1 = 8.70 Hz, J2 = 5.10 Hz, 2H), 7.07 (t, J = 8.70 Hz, 2H), 5.96 (d, J = 9.00 Hz, 1H), 5.55 (br, 1H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 163.1 (d, J = 249 Hz), 153.8, 130.9 (d, J = 7.50 Hz), 129.5, 115.4 (d, J = 21.50 Hz), 94.2, 81.3, 63.8, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C13H15Br2FN2O4Na: 464.9255; found 464.9247. IR (KBr): ν = 3398, 2985, 1697, 1577, 1506, 1369, 1321, 1232, 1167, 850 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(4-bromophenyl)-2-nitroethane (3n)
White solids (483 mg, 96 %). Mp = 129–131 °C. 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 8.40 Hz, 2H), 7.32 (d, J = 8.40 Hz, 2H), 5.93 (d, J = 10.20 Hz, 1H), 5.54 (d, J = 10.20 Hz, 1H), 1.43 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.7, 132.7, 131.5 (2), 130.6 (2), 123.8, 93.7, 81.4, 63.9, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C13H15Br3N2O4Na: 524.8454; found 524.8455. IR (KBr): ν = 3280, 2978, 1687, 1577, 1512, 1369, 1321, 1250, 1163, 837 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(3-fluorophenyl)-2-nitroethane (3o)
White solids (433 mg, 98 %). Mp = 135–137 °C. 1H NMR (300 MHz, CDCl3) δ 7.36 (dd, J1 = 7.80 Hz, J2 = 13.80 Hz, 1H), 7.22 (d, J = 8.40 Hz, 1H), 7.13 (d, J = 9.60 Hz, 1H), 7.11 (t, J = 8.10 Hz, 1H), 5.97 (d, J = 9.00 Hz, 1H), 5.56 (d, J = 9.90 Hz, 1H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 162.2 (d, J = 247 Hz), 153.8, 136.0, 129.9 (d, J = 7.50 Hz), 125.0 (d, J = 3.20 Hz), 116.4 (d, J = 28.20 Hz), 116.1 (d, J = 30.20 Hz), 93.6, 81.4, 63.9, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C13H15Br2FN2O4Na: 464.9255; found 464.9253. IR (KBr): ν = 3253, 3141, 2985, 1695, 1576, 1452, 1379, 1232, 1161, 1018, 775 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(3-bromophenyl)-2-nitroethane (3p)
White solids (433 mg, 86 %). Mp = 155–157 °C. 1H NMR (300 MHz, CDCl3) δ 7.61 (s, 1H), 7.54 (d, J = 8.10 Hz, 1H), 7.37 (d, J = 7.80 Hz, 1H), 7.25 (t, J = 7.80 Hz, 1H), 5.94 (d, J = 10.20 Hz, 1H), 5.56 (d, J = 10.20 Hz, 1H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, DMSO-d6) δ 154.5, 136.8, 132.1(2), 130.0, 129.0, 121.4, 93.8, 79.7, 64.0, 27.9 (3) ppm. MS (ESMS/[M+Na]+): calcd for C13H15Br3N2O4Na: 524.8454; found 524.8464. IR (KBr): ν = 3244, 3143, 2985, 1698, 1576, 1477, 1369, 1255, 1155, 1018, 847 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(3-bromo-4-methoxyphenyl)-2-nitroeth ane (3q)
White solids (469 mg, 88 %). Mp = 157–159 °C. 1H NMR (300 MHz, CDCl3) δ 7.63 (d, J = 2.10 Hz, 1H), 7.33 (dd, J1 = 8.80 Hz, J2 = 2.10 Hz, 1H), 6.87 (d, J = 8.80 Hz, 1H), 5.88 (d, J = 9.90 Hz, 1H), 5.50 (d, J = 9.90 Hz, 1H), 3.90 (s, 3H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 155.9, 154.5, 133.7, 130.7, 127.7, 111.7, 110.3, 94.5, 79.6, 63.6, 56.2, 27.9 (3) ppm. MS (ESMS/[M+Na]+): calcd for C14H17Br3N2O5Na: 554.8560; found 554.8564. IR (KBr): ν = 3269, 3153, 2983, 1695, 1576, 1506, 1369, 1271, 1161, 1022, 845 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(2-methoxyphenyl)-2-nitroethane (3r)
White solids (445 mg, 98 %). Mp = 153–155 °C. 1H NMR (300 MHz, CDCl3) δ 7.37 (t, J = 6.90 Hz, 2H), 7.00–6.91 (m, 2H), 6.29 (d, J = 10.20 Hz, 1H), 6.05 (s, 1H), 3.85 (s, 3H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 157.4, 154.1, 133.3, 130.7, 130.3, 120.5, 111.3, 80.8, 94.6, 61.2, 55.3, 28.1 (3) ppm. MS (ESMS/[M+Na]+): calcd for C14H18Br2N2O5Na: 476.9455; found 476.9447. IR (KBr): ν = 3251, 3138, 2976, 1693, 1576, 1493, 1361, 1248, 1159, 1022, 754 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(3,4-dimethoxyphenyl)-2-nitroethane (3s)
White solids (474 mg, 98 %). Mp = 139–141 °C. 1H NMR (300 MHz, CDCl3) δ 6.98 (dd, J1 = 8.10 Hz, J2 = 2.10 Hz, 1H), 6.89 (d, J = 2.10 Hz, 1H), 6.84 (d, J = 8.10 Hz, 1H), 5.89 (d, J = 9.90 Hz, 1H), 5.54 (d, J = 10.20 Hz, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 1.44 (s, 9H) ppm. 13C NMR (75.45 MHz, DMSO-d6) δ 154.7, 149.4, 148.2, 126.1, 122.6, 113.2, 110.8, 95.4, 79.5, 64.5, 55.7, 55.4, 28.0 (3) ppm. MS (ESMS/[M+Na]+): calcd for C15H20Br2N2O6Na: 506.9561; found 506.9587. IR (KBr): ν = 3359, 2972, 1693, 1574, 1502, 1352, 1315, 1246, 1155, 1024, 845 cm−1.
1-tert-Butoxyl-formamido-2,2-dibromo-1-(4-(tert-butyl)phenyl)-2-nitroethane (3t)
White solids (398 mg, 83 %). Mp = 123–125°C. 1H NMR (300 MHz, CDCl3) δ 7.39–7.32 (m, 4H), 5.95 (d, J = 8.70 Hz, 1H), 5.58 (d, J = 8.70 Hz, 1H), 1.44 (s, 9H), 1.31 (s, 9H) ppm. 13C NMR (75.45 MHz, CDCl3) δ 153.9, 152.5, 130.5, 128.7 (2), 125.4 (2), 94.7, 81.1, 64.2, 34.6, 31.1 (3), 28.1 (3) ppm. MS (ESMS/[M+Na]+): calcd for C17H24Br2N2O6Na: 502.9976; found 502.9997. IR (KBr): ν = 3253, 3145, 2962, 1705, 1577, 1477, 1365, 1257, 1159, 1016, 837, 775 cm−1.
Supplementary Material
ACKNOWLEDGMENT
We gratefully acknowledge the financial support from NIH (R21DA031860-01, Li),the National Natural Science Foundation of China (No. 21102071, Pan), Robert A. Welch Foundation (D-1361, Li), the Fundamental Research Funds for the Key Universities (No. 1107020522 and No. 1082020502, Pan) and the Jiangsu 333 program (Pan).
Footnotes
Supporting Information Available. 1H and 13C NMR spectra of all pure products are available free of charge via the Internet at http://pubs.acs.org.
REFERENCES
- 1 (a).Kemp JEG. In: In ComprehensiVe Organic Synthesis. Trost BM, Fleming I, editors. Vol. 3. Pergamon; Oxford, U.K.: 1991. pp. 471–513. [Google Scholar]; (b) Li G, Kotti S, Timmons C. Eur. J. Org. Chem. 2007:2745–2758. [Google Scholar]; (c) Bovino Michael T., Chemler Sherry R. Angew. Chem. Int. Ed. 2012;16:3923–3927. doi: 10.1002/anie.201109044. [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Cai YF, Liu XH, Li J, Chen WL, Wang WT, Lin LL, Feng XM. Chem.-Eur. J. 2011;17:14916–14921. doi: 10.1002/chem.201102453. [DOI] [PubMed] [Google Scholar]
- 2 (a).De Kimpe N, Verhe R. The Chemistry of R-Haloketones, R-Haloaldehydes, and R-Haloimines. John Wiley & Sons; New York: 1988. [Google Scholar]; (b) Thomas G. Medicinal Chemistry: An Introduction. John Wiley & Sons; New York: 2000. [Google Scholar]
- 3 (a).Daniher FA, Melchior MT, Butler PE. Chem. Commun. 1968;2:931–932. [Google Scholar]; (b) Daniher FA, Butler PE. J. Org. Chem. 1968;33:4336–4340. [Google Scholar]; (c) Daniher FA, Butler PE. J. Org. Chem. 1968;33:2637–2642. doi: 10.1021/jo01271a600. [DOI] [PubMed] [Google Scholar]; (d) Driguez H, Vermes JP, Lessard J. Can. J. Chem. 1978;56:119–130. [Google Scholar]; (e) Lessard J, Driguez H, Vermes JP. Tetrahedron Lett. 1970;11:4887–4890. [Google Scholar]
- 4.Li G, Wei HX, Kim SH, Neighbors M. Org. Lett. 1999;1:395–397. [Google Scholar]
- 5.Wei JF, Chen ZG, Lei W, Zhang LH, Wang MZ, Shi XY, Li RT. Org. Lett. 2009;11:4216–4219. doi: 10.1021/ol9015833. [DOI] [PubMed] [Google Scholar]
- 6 (a).Wu XL, Wang GW. J. Org. Chem. 2007;72:9398–9401. doi: 10.1021/jo701957t. [DOI] [PubMed] [Google Scholar]; (b) Wang GW, Wu XL. Adv. Synth. Catal. 2007;349:1977–1982. [Google Scholar]; (c) Wu XL, Wang GW. Eur. J. Org. Chem. 2008:6239–6246. [Google Scholar]
- 7.Han JL, Zhi SJ, Wang LY, Pan Y, Li G. Eur. J. Org. Chem. 2007:1332–1337. [Google Scholar]
- 8 (a).Sun H, Zhang GQ, Zhi SJ, Han JL, Li G, Pan Y. Org. Biomol. Chem. 2010;8:4236–4239. doi: 10.1039/c0ob00283f. [DOI] [PubMed] [Google Scholar]; (b) Chen ZG, Wei JF, Li RT, Shi XY, Zhao PF. J. Org. Chem. 2009;74:1371–1373. doi: 10.1021/jo8023768. [DOI] [PubMed] [Google Scholar]; (c) Wei JF, Zhang LH, Chen ZG, Shi XY, Cao JJ. Org. Biomol. Chem. 2009;7:3280–3284. doi: 10.1039/b904789a. [DOI] [PubMed] [Google Scholar]; (d) Wu XL, Xia JJ, Wang GW. Org. Biomol. Chem. 2008;6:548–553. doi: 10.1039/b717333d. [DOI] [PubMed] [Google Scholar]; (e) Thakur VV, Talluri SK, Sudalai A. Org. Lett. 2003;5:861–864. doi: 10.1021/ol027530f. [DOI] [PubMed] [Google Scholar]
- 9 (a).Mei HB, Han JL, Li G, Pan Y. RSC Adv. 2011;1:429–433. [Google Scholar]; (b) Chen ZG, Wang Y, Wei JF, Zhao PF, Shi XY. J. Org. Chem. 2010;75:2085–2088. doi: 10.1021/jo9026879. [DOI] [PubMed] [Google Scholar]
- 10 (a).Manzoni MR, Zabawa TP, Kasi D, Chemler SR. Organometallics. 2004;23:5618–5621. [Google Scholar]; (b) Kotti S, Xu X, Wang YN, Headley AD, Li G. Tetrahedron Lett. 2004;45:7209–7212. [Google Scholar]
- 11 (a).Qi X, Lee SH, Kwon JY, Kim Y, Kim SJ, Lee YS, Yoon J. Org. Chem. 2003;68:9140–9143. doi: 10.1021/jo034535x. [DOI] [PubMed] [Google Scholar]; (b) Minakata S, Yoneda Y, Oderaotoshi Y, Komatsu M. Org. Lett. 2006;8:967–969. doi: 10.1021/ol0600178. [DOI] [PubMed] [Google Scholar]; (c) Chen ZG, Zhao PF, Wang Y. Eur. J. Org. Chem. 2011:5887–5893. [Google Scholar]
- 12 (a).Thakur VV, Talluri SK, Sudalai A. Org. Lett. 2003;5:861–864. doi: 10.1021/ol027530f. [DOI] [PubMed] [Google Scholar]; (b) Chen ZG, Wei JF, Li RT, Shi XY, Zhao PF. J. Org. Chem. 2009;74:1371–1373. doi: 10.1021/jo8023768. [DOI] [PubMed] [Google Scholar]; (c) Shaikh TM, Karabal PU, Suryavanshi G, Sudalai A. Tetrahedron Lett. 2009;50:2815. [Google Scholar]; (d) Wei JF, Chen ZG, Lei W, Zhang PF, Wang MZ, Shi XY, Li RT. Org. Lett. 2009;11:4216–4219. doi: 10.1021/ol9015833. [DOI] [PubMed] [Google Scholar]; (e) Chen ZG, Wei JF, Wang MZ, Zhou LY, Zhang CJ, Shi XY. Adv. Synth. Catal. 2009;351:14–15. [Google Scholar]; (f) Cai YF, Liu XH, Jiang J, Chen WL, Lin LL, Feng XM. J. Am. Chem. Soc. 2011;133:5636–5639. doi: 10.1021/ja110668c. [DOI] [PubMed] [Google Scholar]
- 13 (a).Klepacz A, Zwierzak A. Tetrahedron Lett. 2001;42:4539–4540. [Google Scholar]; (b) Sliwinska A, Zwierzak A. Tetrahedron Lett. 2003;44:9323–9325. [Google Scholar]; (c) Sliwinska A, Zwierzak A. Tetrahedron. 2003;59:5927–5934. [Google Scholar]; (d) Mei HB, Xiong YW, Qian Y, Han JL, Li G, Pan Y. RSC Adv. 2012;2:151–155. [Google Scholar]
- 14.Kotti S, Timmons C, Li G. Chem. Biol. Drug. Des. 2006;67:101–114. doi: 10.1111/j.1747-0285.2006.00347.x. [DOI] [PubMed] [Google Scholar]
- 15.Kattamuri PV, Ai T, Pindi S, Sun YW, Gu P, Shi M, Li G. J. Org. Chem. 2011;76:2792–2797. doi: 10.1021/jo200070d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16 (a).Kattuboina A, Li G. Tetrahedron Lett. 2008;49:1573–1577. [Google Scholar]; (b) Kaur P, Pindi S, Wever W, Rajale T, Li G. J. Org. Chem. 2010;75:5144–5150. doi: 10.1021/jo100865q. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Pindi S, Kaur P, Shakya G, Li G. Chem. Biol. Drug Design. 2011;77:20–29. doi: 10.1111/j.1747-0285.2010.01047.x. [DOI] [PubMed] [Google Scholar]
- 18(a).Chen ZG, Zhou JM, Wang Y, Li WL. Acta Chim. Sinica. 2011;69:2851–2858. For both reported anhydrous Na3PO4- and K3PO4-catalyzed aminohalogenation systems, 20 - 50 mol% of catalyst was required.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
